Regen BioPharma Inc (RGBP)

[bay8605]

Food for Thought
Eli Lilly has been busy.

Lilly and Precision BioSciences Announce Genome Editing Research Collaboration and License Agreement
November 20, 2020
Eli Lilly and Company (NYSE: LLY) and Precision BioSciences, Inc. (Nasdaq: DTIL) today announced a research collaboration and exclusive license agreement to utilize Precision's proprietary ARCUS®...

Lilly Announces Agreement to Acquire Prevail Therapeutics
December 15, 2020
Eli Lilly and Company (NYSE: LLY) and Prevail Therapeutics Inc. (NASDAQ: PRVL) today announced a definitive agreement for Lilly to acquire Prevail for $22.50 per share in cash (or an aggregate of...
SIDE NOTE
Prevail Therapeutics stock nearly doubles after Eli Lilly buyout ...https://www.marketwatch.com › story › prevail-therapeuti...
Dec 15, 2020 — Under terms of the deal, Lilly will buy Prevail for $22.50 per share in cash, which is 84% above Monday's closing price of $12.50, .

Lilly Announces 2021 Financial Guidance, Updates 2020 Guidance
December 15, 2020
Eli Lilly and Company (NYSE: LLY) today announced its 2021 financial guidance, highlighted by volume-based revenue growth, increased investment in research and development, operating margin...

Lilly and Merus NV Announce Collaboration to Discover Novel T-Cell Re-Directing Bispecific Antibodies
January 19, 2021
Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Merus N.V. (NASDAQ: MRUS), a clinical-stage oncology company developing multi-specific...

Lilly and Asahi Kasei Pharma Announce License Agreement for Chronic Pain Drug Candidate
January 28, 2021
Eli Lilly and Company (NYSE: LLY) and Asahi Kasei Pharma Corporation today announced a license agreement whereby Lilly will acquire the exclusive rights for AK1780 from Asahi Kasei Pharma. AK1780...

Lilly and Rigel Enter Strategic Collaboration to Develop RIPK1 Inhibitors for the Potential Treatment of Immunological and Neurodegenerative Diseases
February 18, 2021
Eli Lilly and Company (NYSE: LLY) and Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced a global exclusive license agreement and strategic collaboration to co-develop and commercialize...

Lilly and Biolojic Design Announce Research Collaboration to Discover and Develop Antibody Therapies for Diabetes
March 08, 2021
Eli Lilly and Company (NYSE: LLY) and Biolojic Design Ltd. ("Biolojic"), a biotechnology company that computationally designs functional antibodies, today announced a research collaboration and...

Lilly and MiNA Therapeutics Announce saRNA Research Collaboration
May 11, 2021
Eli Lilly and Company (NYSE: LLY) and MiNA Therapeutics Limited, a pioneer in RNA activation therapeutics, today announced a global research collaboration to develop novel drug candidates using...

Lilly Announces Acquisition of Protomer Technologies
July 14, 2021
Eli Lilly and Company (NYSE: LLY) today announced the acquisition of Protomer Technologies ("Protomer"), a private biotech company. Protomer's proprietary peptide- and protein-engineering platform...

Lilly and Kumquat Biosciences Announce Collaboration to Discover and Develop Novel Small Molecules that Stimulate Tumor-Specific Immune Responses
July 29, 2021
Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Kumquat Biosciences today announced an exclusive collaboration focused on the discovery,...

Kumquat is eligible to receive over $2 billion in potential milestone payments based on the achievement of preclinical, development and future commercial milestones